ClinicalTrials.Veeva

Menu

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

M

MapLight Therapeutics

Status and phase

Invitation-only
Phase 2

Conditions

Psychosis Associated With Alzheimer's Disease

Treatments

Drug: ML-007C-MA

Study type

Interventional

Funder types

Industry

Identifiers

NCT07459660
2025-521757-16-00 (EU Trial (CTIS) Number)
ML-007C-MA-222
2025

Details and patient eligibility

About

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

Enrollment

210 estimated patients

Sex

All

Ages

55 to 91 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  1. Willing and able to provide written informed consent, or, if deemed lacking in the capacity to provide informed consent, the following requirements for consent must be met:

    1. The participant's LAR must provide written informed consent. AND
    2. The participant will provide informed assent.
  2. Has completed the Double-Blind Treatment Period of an antecedent study with ML-007C-MA (ie, ML-007C-MA-221).

  3. May benefit from long-term therapy with open-label ML-007C-MA treatment, in the judgment of the investigator.

  4. Has a designated study care partner who is in contact with the participant frequently enough to accurately report on the participant's symptoms and adherence to study drug.

  5. Resides in a stable living environment (eg, home, residential assisted living, or nursing home facility) and is expected to remain in the living situation throughout the study.

Exclusion Criteria

  1. Under the care of hospice, bed-bound, or receiving end-of-life palliative care.
  2. Requires treatment with protocol-defined prohibited medications.
  3. Has developed a new or worsening medical comorbidity during or since the antecedent study that, in the opinion of the investigator and/or medical monitor, would compromise participant safety, interfere with the participant's ability to comply with study procedures, would preclude obtaining voluntary consent/assent, and/or would substantially impair the evaluation of study assessments.
  4. Has or had a clinically significant abnormal physical examination, vital sign, ECG or clinical laboratory safety result during or since the antecedent study that would compromise participant safety, interfere with the participant's ability to comply with study procedures, and/or would confound the interpretation of the outcome measures in the study in the opinion of the investigator.
  5. Has developed an allergy or other intolerance to ML-007C-MA, its active ingredients or their excipients since the antecedent study.
  6. Has an elevated risk of suicidal behavior.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

210 participants in 1 patient group

ML-007C-MA
Experimental group
Treatment:
Drug: ML-007C-MA

Trial contacts and locations

11

Loading...

Central trial contact

Clinical Trials Contact Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems